Xintiandi Pharmaceuticals' "Financial Mishap" Scandal: Compliance Bottom Line Breached, Governance Concerns Mount Amid Slumping Performance

Log in to the Sina Finance APP and search for [Information Disclosure] to view more evaluation levels.

In just one day, dual regulatory scrutiny has “named names”—for the GEM-listed company Xintiandi Pharmaceutical (301277), March 16, 2026, is undoubtedly a compliance “Waterloo.” This globally significant producer of amoxicillin side chains has exposed deep shortcomings in internal governance due to a series of procedural violations in fundraising management. Amid already pressurized performance, this incident not only sounded the alarm for the company’s internal controls but may also undermine market trust in its management capabilities.

01 Disordered Procedures: A case of “acting first and reporting later” in financial management

According to the regulatory letter issued by the Shenzhen Stock Exchange, Xintiandi Pharmaceutical’s violations in fundraising management show evident randomness. Specifically, the company continued to “habitually” purchase financial products worth up to 122 million yuan beyond the effective period authorized by the board of directors; additionally, another 65 million yuan in products purchased during the authorized period was not redeemed within the authorization period upon maturity. It was only on February 27 of this year that the company publicly “ratified” the above behaviors.

This “act first, explain later” approach directly infringes upon the regulatory red lines for fundraising management on the GEM. More critically, the involved parties include core management personnel—Chairman Xie Jianzhong, General Manager Zhang Luwei, CFO Wang Qingkui, and Secretary of the Board Xie Yushan—who have all been held accountable, reflecting that the issue is not merely an operational error in individual positions but may indicate systemic execution deviations in the company’s governance mechanism.

02 Compliance Bottom Line: “No loss incurred” cannot be used as a reason for exemption

Although the company later explained that all related financial products have been redeemed and no financial losses were incurred, in the context of listed company governance, procedural compliance and the timeliness and accuracy of information disclosure are baseline requirements, and outcomes cannot be the sole measure of merit. The use of raised funds is subject to strict legal constraints, and both management authority and authorization periods are rigid indicators; any “habitual operations” or “post hoc ratifications” essentially constitute a disregard for shareholder rights and regulatory rules.

The Henan Securities Regulatory Bureau has decided to record this violation in the integrity files of the securities and futures market, which will have a lasting impact on the market reputation of the listed company. Under the registration system, the compliance of information disclosure directly relates to a company’s refinancing ability and market valuation, and a “stain” in the integrity file will undoubtedly increase the company’s future communication costs in the capital market.

03 Performance Reversal Coupled with Internal Control Risks, Investor Confidence Faces Dual Tests

At the time of this regulatory storm, Xintiandi Pharmaceutical was already mired in operational pressure. The Q3 2025 report showed that the company achieved revenue of 481 million yuan, a year-on-year decline of 10.42%; the net profit attributable to the parent company was 91.9 million yuan, a significant year-on-year decrease of 35.19%. The obvious “reversal” in performance has already raised doubts about the company’s growth potential, and the outbreak of this compliance crisis further amplified external skepticism about its internal management capabilities.

For companies experiencing a performance downturn, internal control loopholes often have a strong “spillover effect”—not only can they trigger sustained regulatory attention, but they can also provoke a trust crisis among investors. Once the market fundamentally questions the normativity of corporate governance, the valuation logic will inevitably be impacted.

Conclusion: Repairing Compliance Shortcomings is More Important Than Explanations

The issues exposed by Xintiandi Pharmaceutical this time, at first glance, seem to be “procedural flaws” in financial management, but they actually reflect deep-seated shortcomings in the company’s internal control execution and compliance culture construction. In the dual context of performance pressure and tightening regulation, if the company’s management merely regards this incident as an accidental operational error while neglecting to address systemic governance deficiencies, it may lay greater hidden dangers for future development.

How to swiftly improve the mechanism for using raised funds, strengthen executives’ compliance awareness, and rebuild investor trust without affecting normal operations has become an unavoidable question for Xintiandi Pharmaceutical. The capital market is never short of stories of “getting up after a fall,” but the premise is that companies must genuinely demonstrate respect for regulations and commitment to governance.

This article is generated in conjunction with AI tools.

Massive information and precise interpretation are available in the Sina Finance APP.

Editor: AI Observer